Comparison of Co2 Laser Versus Co2 Laser With PRP in Scars
NCT ID: NCT05887232
Last Updated: 2023-06-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
60 participants
INTERVENTIONAL
2022-11-01
2023-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Study design: Randomized-controlled trial (RCT). Study setting and duration: Dermatology Department, CMH-Abbottabad, November 2022/April 2023.
Methodology: The sample size of 60 patients, age 18 to 50 years, was calculated by using Openepi app and the non-probability consecutive sampling technique was used. Patient in group A received FCL treatment's four sessions with four weeks apart, whereas Group B received four PRP and FCL sessions. The Quartile grading scale (score 0 is \<25%, score 1 is 25-50%, score 2 is 51-75% and score 3 is \>75% improvement) was used to assess the patient's clinical improvement at 4 weeks after each session. To determine statistical significance χ2-square test, taking p-value \<0.05 as significant, was used.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Lasers in the Treatment of Scars
NCT02988622
Ablative 10600 nm Fractional Laser Therapy for the Treatment of Scars
NCT01358838
Treatment of Hypertrophic Scars Using Fractional Laser and Fractional Laser-assisted Topical Corticosteroid Delivery
NCT02487212
The Use of Fractional Ablative CO2 Laser vs Control on Acute Traumatic Injuries to Prevent Scar Formation
NCT03888703
Laser Treatment for the Improvement of Scars and Scleroderma
NCT04567537
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fractional Co2 laser
Patient in group A received FCL treatment's four sessions four weeks apart.
Fractional CO2 laser
Patient in group A received FCL treatments four sessions with four weeks apart
Platelet Rich Plasma
Group B received fractional CO2 with four Platelet Rich Plasma sessions,4 weeks apart.
Fractional CO2 with Platelet Rich Plasma
Group B received four PRP and FCL sessions 4 weeks apart
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fractional CO2 laser
Patient in group A received FCL treatments four sessions with four weeks apart
Fractional CO2 with Platelet Rich Plasma
Group B received four PRP and FCL sessions 4 weeks apart
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Fitzpatrick skin type III-V
* Presented with post-acne, post traumatic or post burn scars
* all those patients emotionally balanced with realistic expectations were included in the study.
Exclusion Criteria
* if they had an active infection or inflammatory skin condition
* having a history of malignancy
* a known connective tissue illness
* history of excessive bleeding or keloids
* unrealistic expectations
* pregnant or breastfeeding.
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Combined Military Hospital Abbottabad
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zahra Nigar
Principle Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dr.Zahra Nigar
Abbottabad, KPK, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CMHAbbottabad1988
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.